MX2011009174A - Formulaciones de insulina para captacion rapida. - Google Patents

Formulaciones de insulina para captacion rapida.

Info

Publication number
MX2011009174A
MX2011009174A MX2011009174A MX2011009174A MX2011009174A MX 2011009174 A MX2011009174 A MX 2011009174A MX 2011009174 A MX2011009174 A MX 2011009174A MX 2011009174 A MX2011009174 A MX 2011009174A MX 2011009174 A MX2011009174 A MX 2011009174A
Authority
MX
Mexico
Prior art keywords
formulations
insulin
preferred
subcutaneous injection
insulin formulations
Prior art date
Application number
MX2011009174A
Other languages
English (en)
Inventor
Ming Liu
Solomon S Steiner
Roderike Pohl
Robert Hauser
Original Assignee
Biodel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42238758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011009174(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biodel Inc filed Critical Biodel Inc
Publication of MX2011009174A publication Critical patent/MX2011009174A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente formulaciones de insulina inyectables con estabilidad mejorada y rápido comienzo de acción. Las formulaciones pueden ser para la administración subcutánea, intradérmica o intramuscular. En la modalidad preferida, las formulaciones se administran por la vía de la inyección subcutánea. Las formulaciones contienen insulina en combinación con un quelante y agente de disolución y opcionalmente excipientes adicionales. En la modalidad preferida, la formulación contiene insulina humana, un quelante de zinc tal como EDTA y un agente de disolución tal como ácido cítrico o citrato de sodio. Estas formulaciones se absorben rápidamente en la corriente sanguínea cuando se administran mediante la inyección subcutánea.
MX2011009174A 2009-03-03 2010-03-03 Formulaciones de insulina para captacion rapida. MX2011009174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/397,219 US9060927B2 (en) 2009-03-03 2009-03-03 Insulin formulations for rapid uptake
PCT/US2010/026073 WO2010102020A1 (en) 2009-03-03 2010-03-03 Insulin formulations for rapid uptake

Publications (1)

Publication Number Publication Date
MX2011009174A true MX2011009174A (es) 2011-09-26

Family

ID=42238758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009174A MX2011009174A (es) 2009-03-03 2010-03-03 Formulaciones de insulina para captacion rapida.

Country Status (24)

Country Link
US (1) US9060927B2 (es)
EP (3) EP3811968A1 (es)
JP (1) JP5794736B2 (es)
KR (1) KR20120006991A (es)
CN (1) CN102341119A (es)
AU (1) AU2010221397B2 (es)
BR (1) BRPI1012642A2 (es)
CA (1) CA2754251C (es)
CY (2) CY1120583T1 (es)
DK (2) DK2403520T3 (es)
ES (2) ES2845177T3 (es)
HR (2) HRP20181035T1 (es)
HU (1) HUE039333T2 (es)
IL (1) IL214699A (es)
LT (2) LT2403520T (es)
MX (1) MX2011009174A (es)
NZ (1) NZ595445A (es)
PL (1) PL2403520T3 (es)
PT (1) PT2403520T (es)
RU (1) RU2506945C2 (es)
SG (1) SG173858A1 (es)
SI (2) SI2403520T1 (es)
TR (1) TR201809817T4 (es)
WO (1) WO2010102020A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
CA2805031A1 (en) * 2010-07-07 2012-01-12 Biodel, Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
KR101810055B1 (ko) * 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
JP6322642B2 (ja) 2012-11-13 2018-05-09 アドシア 置換されたアニオン性化合物を含有する速効型インスリン製剤
US20140336610A1 (en) 2013-04-09 2014-11-13 Biodel, Inc. Methods and devices for point of use mixing of pharmaceutical formulations
BR112016016290A2 (pt) * 2014-01-13 2017-10-03 Thermalin Diabetes Llc Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
KR102569743B1 (ko) * 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
TW201630622A (zh) * 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CN107436311B (zh) * 2016-05-25 2021-11-19 正大天晴药业集团股份有限公司 一种鉴别胰岛素单体或胰岛素多聚体的方法
CA3034971A1 (en) 2016-09-29 2018-04-05 Arecor Limited A pharmaceutical insulin formulation
US20180318426A1 (en) * 2017-05-05 2018-11-08 Merck Sharp & Dohme Corp. Pharmaceutical formulations comprising insulin or insulin analogs conjugated to fucose for providing a basal pharmacodynamic profile
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
MX2019014195A (es) 2017-06-01 2020-01-27 Lilly Co Eli Composiciones de insulina de rapida accion.
CA3075799A1 (en) * 2017-09-27 2019-04-04 Becton, Dickinson And Company Fluid delivery device with leak detection
IL277720B2 (en) 2018-04-04 2024-03-01 Arecor Ltd A medical infusion pump system for administration of an insulin compound
WO2019193349A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN111989088A (zh) 2018-04-04 2020-11-24 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143590A (en) 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2819999A (en) 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US3649456A (en) 1969-09-08 1972-03-14 Rohm & Haas Separation of polypeptide substances with macroreticular resins
US3683635A (en) 1970-12-07 1972-08-15 Mario Campanelli Freeze stabilized insulin
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
GB1479283A (en) 1973-07-23 1977-07-13 Bespak Industries Ltd Inhaler for powdered medicament
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
DE2629568C3 (de) 1976-07-01 1981-09-10 Hoechst Ag, 6000 Frankfurt Verfahren zur Reinigung von Insulin, seinen Analogen und Derivaten
US4211769A (en) 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4377482A (en) 1978-04-28 1983-03-22 Salk Institute For Biological Studies Mobile phase for liquid chromatography
US4196196A (en) 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4272398A (en) 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
DK147437A (en) 1980-02-11 1900-01-01 Process for preparing human insulin or threonine B30 esters of human insulin, or a salt or complex thereof
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
US4364385A (en) 1981-03-13 1982-12-21 Lossef Steven V Insulin delivery device
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
EP0083619A1 (en) 1981-07-17 1983-07-20 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
KR890000664B1 (ko) 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4459226A (en) 1982-02-26 1984-07-10 Eli Lilly And Company Process for recovering insulin
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4946828A (en) 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
JPS6320301A (ja) 1986-07-11 1988-01-28 Dainichi Color & Chem Mfg Co Ltd キトサン微小粒体
US5042975A (en) 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
NZ221411A (en) 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
JPH02104531A (ja) 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
JPH0739339B2 (ja) 1989-05-01 1995-05-01 アルカーメス コントロールド セラピューティクス,インコーポレイテッド 生物活性を有する分子の小粒子の製造方法
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
DE3942145A1 (de) 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
JPH05507090A (ja) 1990-05-08 1993-10-14 リポサーム テクノロジー インコーポレイテッド 直接噴霧乾燥された薬剤/脂質粉末組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
SE9002895D0 (sv) 1990-09-12 1990-09-12 Astra Ab Inhalation devices for dispensing powders i
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
GB9024760D0 (en) 1990-11-14 1991-01-02 Riker Laboratories Inc Inhalation device and medicament carrier
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU1442592A (en) 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5492112A (en) 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
CA2070061C (en) 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
EP0592540B1 (en) 1991-07-02 2000-01-26 Inhale, Inc. Method and device for delivering aerosolized medicaments
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5329976A (en) 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
JP3121080B2 (ja) 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション カプセル封入用溶液
DE69306755T2 (de) 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
EP0558879B1 (en) 1992-03-04 1997-05-14 Astra Aktiebolag Disposable inhaler
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
EP0606486B1 (en) 1992-06-12 2001-08-29 Teijin Limited Pharmaceutical preparation for intra-airway administration
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
JP2912453B2 (ja) 1992-10-19 1999-06-28 デュラ・ファーマシューティカルズ・インコーポレイテッド 乾燥粉末の吸入器
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
WO1996010996A1 (en) 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
CN1056618C (zh) 1993-09-17 2000-09-20 诺沃挪第克公司 酰化的胰岛素和含有这种胰岛素的药物组合物
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
EP0655237A1 (de) 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5484606A (en) 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
ES2316917T3 (es) 1994-03-07 2009-04-16 Nektar Therapeutics Metodos y composiciones para suministro pulmonar de insulina.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
AU2517095A (en) 1994-05-19 1995-12-18 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
IL110024A (en) 1994-06-15 1998-04-05 Yissum Res Dev Co Controlled release oral drug delivery system containing hydrogel- forming polymer
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
EP0805149A4 (en) 1994-12-01 1998-03-11 Toyama Chemical Co Ltd NEW 2,3-DICETOPIPERAZINE DERIVATIVE OR SALT THEREOF
US5901703A (en) 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
DE69622421T2 (de) 1995-11-13 2003-03-20 Medtronic Minimed Inc Verfahren und zusammensetzungen zur verabreichung monomerer proteine
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
RU2198181C2 (ru) 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
JP2001518916A (ja) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ 結晶インスリンを含有する肺投与のための治療用粉末調合物
DE69806582T2 (de) 1997-03-20 2003-02-13 Novo Nordisk As Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
US6165484A (en) 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
ES2293875T3 (es) 1997-10-01 2008-04-01 Novadel Pharma Inc. Aerosol bucal no polar.
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
AU3421099A (en) 1998-04-09 1999-11-01 Axiva Gmbh Particulate active agent support for pulmonary application
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6440463B1 (en) 1999-04-05 2002-08-27 Pharmaceutical Discovery Corporation Methods for fine powder formation
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP2280020B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
NZ516811A (en) 1999-07-23 2002-10-25 Pharmaceutical Discovery Corp Unit dose capsules and dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DK1666028T3 (da) 1999-10-29 2010-06-21 Novartis Ag Tørre pulversammensætninger med forbedret dispersitet
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
WO2001064182A2 (en) 2000-02-28 2001-09-07 Vectura Limited Improvements in or relating to the delivery of oral drugs
US6432383B1 (en) 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
EP1438019A1 (en) 2001-10-24 2004-07-21 PARI GmbH Spezialisten für effektive Inhalation Kit for the preparation of a pharmaceutical composition
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20030143195A1 (en) 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US7255102B2 (en) 2002-02-01 2007-08-14 Generex Pharmaceuticals Inc. Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
US20030194420A1 (en) 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
JP2006512409A (ja) 2002-10-31 2006-04-13 ユーエムディー, インコーポレイテッド 薬物送達用治療組成物で被覆上皮に対するもの及びそれを介するもの
BR0316685A (pt) 2002-12-17 2005-11-01 Nastech Pharm Co Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
EP1605916A4 (en) 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE
US20040171518A1 (en) 2003-02-27 2004-09-02 Medtronic Minimed, Inc. Compounds for protein stabilization and methods for their use
CA2518216C (en) 2003-03-06 2017-05-09 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20050203001A1 (en) 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
WO2005067898A2 (en) 2004-01-07 2005-07-28 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
EP1708738B1 (en) 2004-01-12 2016-05-04 MannKind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
WO2005086814A2 (en) 2004-03-09 2005-09-22 The Uab Research Foundation Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (gsk-3)
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
DK2319500T3 (da) 2004-03-12 2013-02-04 Biodel Inc Hurtigtvirkende sammensætninger til afgivelse af lægemiddel
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080102114A1 (en) 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
US7964012B2 (en) * 2005-08-03 2011-06-21 Hollingsworth & Vose Company Filter media with improved conductivity
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー,インコーポレイテッド 速効型インスリンの経鼻投与
CA2630586A1 (en) * 2005-11-22 2007-05-31 Dia-B Tech Limited Compositions and methods for treatment of diabetes
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
FR2896164B1 (fr) * 2006-01-18 2008-07-04 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル, インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008013955A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
WO2008016729A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2234644B1 (en) 2008-01-04 2013-07-31 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN102470165B (zh) 2009-06-26 2014-12-24 诺沃-诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂

Also Published As

Publication number Publication date
US20100227795A1 (en) 2010-09-09
PL2403520T3 (pl) 2018-10-31
AU2010221397A1 (en) 2011-10-27
KR20120006991A (ko) 2012-01-19
DK2403520T3 (en) 2018-07-23
WO2010102020A1 (en) 2010-09-10
IL214699A (en) 2015-11-30
EP2403520B1 (en) 2018-04-25
LT3372238T (lt) 2021-02-10
SI3372238T1 (sl) 2021-01-29
AU2010221397B2 (en) 2013-07-04
IL214699A0 (en) 2011-11-30
EP3811968A1 (en) 2021-04-28
ES2680903T3 (es) 2018-09-11
LT2403520T (lt) 2018-08-10
NZ595445A (en) 2013-10-25
EP3372238B1 (en) 2020-11-18
JP2012519695A (ja) 2012-08-30
CA2754251A1 (en) 2010-09-10
DK3372238T3 (da) 2020-11-30
EP2403520A1 (en) 2012-01-11
HRP20181035T1 (hr) 2018-08-24
PT2403520T (pt) 2018-07-30
CA2754251C (en) 2018-07-17
TR201809817T4 (tr) 2018-07-23
US9060927B2 (en) 2015-06-23
SI2403520T1 (sl) 2018-09-28
ES2845177T3 (es) 2021-07-26
RU2011139984A (ru) 2013-04-10
SG173858A1 (en) 2011-09-29
HUE039333T2 (hu) 2018-12-28
CY1120583T1 (el) 2019-07-10
CY1123597T1 (el) 2021-10-29
JP5794736B2 (ja) 2015-10-14
BRPI1012642A2 (pt) 2016-04-05
RU2506945C2 (ru) 2014-02-20
EP3372238A1 (en) 2018-09-12
HRP20201969T1 (hr) 2021-02-05
CN102341119A (zh) 2012-02-01

Similar Documents

Publication Publication Date Title
MX2011009174A (es) Formulaciones de insulina para captacion rapida.
MX2010003776A (es) Composiciones de insulina inyectables de accion rapida.
IN2014DN08417A (es)
WO2014093127A3 (en) Method of administering nicotine, thc, tobacco, cannabidiol or base alkaloid and absorption conditioning unit
HK1099707A1 (en) Insulin compositions with improved absorption
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
AR081200A1 (es) Formulaciones de insulina de accion prolongada
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2010004388A (es) Formulaciones de hormona paratiroidea y usos de las mismas.
GB2491328A (en) Immediate/delayed drug delivery
MX349176B (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
NZ610441A (en) Methods for enhancing oxygenation of jeopardized tissue
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
MX2009014178A (es) Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
EP2745856A3 (en) Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES
WO2011066201A3 (en) Methods and systems for treating and preventing cardiac injury in dystrophic subjects
MD84Z (ro) Metodă de hemostază după extracţia dentară
Bae et al. A Case of Amiodarone Hepatotoxicity in Patient with Atrial Fibrillation

Legal Events

Date Code Title Description
FG Grant or registration